Relevance of pituitary gland magnetic resonance imaging results with clinical and laboratory findings in growth hormone deficiency


KARA Ö., Esen İ., TEPE D., GÜLLEROĞLU N. B., Tayfun M.

Medical Science Monitor, cilt.24, ss.9473-9478, 2018 (SCI-Expanded, Scopus)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 24
  • Basım Tarihi: 2018
  • Doi Numarası: 10.12659/msm.911977
  • Dergi Adı: Medical Science Monitor
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.9473-9478
  • Anahtar Kelimeler: Dwarfism, Pituitary, Growth Hormone, Magnetic Resonance Imaging
  • Sağlık Bilimleri Üniversitesi Adresli: Evet

Özet

Background: The present study investigated the relationship between detection of organic pathologies with magnetic resonance imaging of the pituitary gland, clinical and laboratory findings, and treatment response. Material/Methods: The study included a total of 183 patients who had isolated growth hormone deficiency, received at least 1 year of treatment, returned regularly for follow-ups, and whose pituitary magnetic resonance images were available. The patients were divided into 2 groups: those with and without pathological evidence with magnetic resonance imaging. Clinical and laboratory features and treatment responses were compared between patients with and without pathological evidence with magnetic resonance imaging. Results: Of the 183 patients, 105 were females and 78 were males, and 114 patients (62.2%) were prepubertal and 69 patients (37.8%) were pubertal. Their mean age was 10.01±3.25 years (1–17.6 years). Pituitary images of 153 (83.6%) patients were normal. Of the patients with detected pathologies (16.4%), 19 (10,4%) had pituitary hy-poplasia, 5 (2.7%) had partial empty sella, 3 (1.7%) had ectopic neurohypophysis and 3 (1.7%) had empty sella, pineal, and arachnoid cyst. A statistically significant increase was observed in the height increase rate after treatment compared to before treatment in both groups (p<0.001). However, the group with pathology had a statistically significant (p=0. 007) post-treatment increase height rate. Although in the group with pathology there was a lower L-DOPA and clonidine peak GH response, there was not any statistically significant difference between the 2 groups (p=0.051, p=0.113). Pituitary gland length was also shorter in the group with pathology compared to the group without pathology (P<0.001). Conclusions: Magnetic resonance imaging is a useful tool in assessing GH deficiency pathogenesis and in predicting treatment response.